Dr. Marty Makary resigns as head of the U.S. Food and Drug Administration (FDA), according to reporting from multiple outlets. The resignation further widens a leadership gap that has already existed at the U.S. Department of Health and Human Services, the federal department that oversees the FDA. Both sources frame the move as part of a broader period of instability at the senior leadership level within the health department. The articles do not describe new policy actions or specific regulatory changes tied to the resignation, focusing instead on its implications for leadership continuity. The resignation leaves the FDA without its top official and increases uncertainty about who will manage the agency’s day-to-day oversight and direction in the interim. Further reporting is expected to clarify the timing of the departure, the nature of the transition, and any interim leadership arrangements while the department addresses the gap at both the FDA and Department of Health and Human Services levels.